173 related articles for article (PubMed ID: 16961724)
1. CPU86017: a novel Class III antiarrhythmic agent with multiple actions at ion channels.
Dai DZ
Cardiovasc Drug Rev; 2006; 24(2):101-15. PubMed ID: 16961724
[TBL] [Abstract][Full Text] [Related]
2. Chiral separation of racemate CPU86017, an anti-arrhythmic agent, produces stereoisomers possessing favourable ion channel blockade and less alpha-adrenoceptor antagonism.
Li N; Yang L; Dai DZ; Wang QJ; Dai Y
Clin Exp Pharmacol Physiol; 2008 May; 35(5-6):643-50. PubMed ID: 18177475
[TBL] [Abstract][Full Text] [Related]
3. Abrupt changes in FKBP12.6 and SERCA2a expression contribute to sudden occurrence of ventricular fibrillation on reperfusion and are prevented by CPU86017.
Na T; Huang ZJ; Dai DZ; Zhang Y; Dai Y
Acta Pharmacol Sin; 2007 Jun; 28(6):773-82. PubMed ID: 17506935
[TBL] [Abstract][Full Text] [Related]
4. Induced ion currents and the endothelin pathway as targets for anti-arrhythmic agents.
Dai DZ; Dai Y
Curr Opin Investig Drugs; 2008 Sep; 9(9):1001-8. PubMed ID: 18729007
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory factors that contribute to upregulation of ERG and cardiac arrhythmias are suppressed by CPU86017, a class III antiarrhythmic agent.
Du RH; Yi HW; Dai DZ; Tang WH; Dai Y
J Pharm Pharmacol; 2008 Aug; 60(8):1089-95. PubMed ID: 18644201
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017.
Na T; Dai DZ; Tang XY; Dai Y
Naunyn Schmiedebergs Arch Pharmacol; 2007 Mar; 375(1):39-49. PubMed ID: 17287947
[TBL] [Abstract][Full Text] [Related]
7. Effects of the novel amiodarone-like compound SAR114646A on cardiac ion channels and ventricular arrhythmias in rats.
Goegelein H; Gautier P; Roccon A; O'Connor S; Ruetten H
Naunyn Schmiedebergs Arch Pharmacol; 2011 Sep; 384(3):231-44. PubMed ID: 21766160
[TBL] [Abstract][Full Text] [Related]
8. Failure of antiarrhythmic drugs to affect epicardial delay during acute experimental coronary artery occlusion and reperfusion: correlation with lack of antiarrhythmic efficacy.
Naito M; Michelson EL; Kmetzo JJ; Kaplinsky E; Dreifus LS
J Pharmacol Exp Ther; 1981 Aug; 218(2):475-80. PubMed ID: 7252847
[TBL] [Abstract][Full Text] [Related]
9. Model systems for the discovery and development of antiarrhythmic drugs.
Nattel S; Duker G; Carlsson L
Prog Biophys Mol Biol; 2008; 98(2-3):328-39. PubMed ID: 19038282
[TBL] [Abstract][Full Text] [Related]
10. [Tetrodotoxin potentiation of the antiarrhythmic action of lidocaine in the late stage of experimental myocardial infarct].
Rozenshtraukh LV; Aniukhovskiĭ EP; Beloshapko GG
Biull Eksp Biol Med; 1981; 91(1):38-40. PubMed ID: 6163491
[TBL] [Abstract][Full Text] [Related]
11. Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias.
Dai DZ; Yu F
Acta Pharmacol Sin; 2005 Aug; 26(8):918-25. PubMed ID: 16038623
[TBL] [Abstract][Full Text] [Related]
12. N-(2,6-Dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165): a new potent and long-acting antiarrhythmic agent.
Aisaka K; Hidaka T; Inomata N; Hamasaki S; Ishihara T; Morita M
Arzneimittelforschung; 1985; 35(8):1239-45. PubMed ID: 4074441
[TBL] [Abstract][Full Text] [Related]
13. Dispersion of ventricular mRNA of RyR2 and SERCA2 associated with arrhythmogenesis in rats.
Wang HL; Dai DZ; Gao E; Zhang YP; Lu F
Acta Pharmacol Sin; 2004 Jun; 25(6):738-43. PubMed ID: 15169625
[TBL] [Abstract][Full Text] [Related]
14. Vulnerable substrate and multiple ion channel disorder in a diseased heart will be new targets for antiarrhythmic therapy.
Dai DZ
Acta Pharmacol Sin; 2000 Apr; 21(4):289-95. PubMed ID: 11324452
[TBL] [Abstract][Full Text] [Related]
15. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
Fuchs T; Groysman R; Meilichov I
Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
[TBL] [Abstract][Full Text] [Related]
16. Future of antiarrhythmic drugs.
Darbar D; Roden DM
Curr Opin Cardiol; 2006 Jul; 21(4):361-7. PubMed ID: 16755206
[TBL] [Abstract][Full Text] [Related]
17. Simulated interactions between a Class III antiarrhythmic drug and a figure 8 reentry.
Seigneuric RG; Chassé JL; Auger P; Bardou A
Acta Biotheor; 2005; 53(4):265-75. PubMed ID: 16583269
[TBL] [Abstract][Full Text] [Related]
18. Effects of SEA0400, a Na+/Ca2+ exchange inhibitor, on ventricular arrhythmias in the in vivo dogs.
Nagasawa Y; Zhu BM; Chen J; Kamiya K; Miyamoto S; Hashimoto K
Eur J Pharmacol; 2005 Jan; 506(3):249-55. PubMed ID: 15627435
[TBL] [Abstract][Full Text] [Related]
19. Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia.
Hashimoto K; Satoh H; Shibuya T; Imai S
J Pharmacol Exp Ther; 1982 Dec; 223(3):801-10. PubMed ID: 7143241
[TBL] [Abstract][Full Text] [Related]
20. Druggable targets for sudden cardiac death prevention: lessons from the past and strategies for the future.
Clements-Jewery H; Andrag E; Curtis MJ
Curr Opin Pharmacol; 2009 Apr; 9(2):146-53. PubMed ID: 19167272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
